Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma

International Journal of Hematology

Volumn 93, Issue 2, 2011, Pages 257-259

  Ozaki, Shuji ^a,b   Harada, Takeshi ^a,b   Fujii, Shiro ^a,b   Nakamura, Shingen ^a,b   Miki, Hirokazu ^a,b   Nakano, Ayako ^a,b   Kagawa, Kumiko ^a,b   Takeuchi, Kyoko ^a,b   Abe, Masahiro ^a,b   Matsumoto, Toshio ^a,b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; C REACTIVE PROTEIN; DEXAMETHASONE; DOXORUBICIN; FIBRINOGEN; HEMOGLOBIN; IMMUNOGLOBULIN G; LENALIDOMIDE; M PROTEIN; VINCRISTINE;

ACNE; ADULT; ARTHRALGIA; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; FATIGUE; FEVER; HUMAN; HYPERTENSION; INFLAMMATION; LETTER; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE;

EID: 79952252906     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0775-1     Document Type: Letter

References (9)

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-57.
2. M Dimopoulos A Spencer M Attal HM Prince JL Harousseau A Dmoszynska, et al. 2007 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2123 2132 1:CAS:528:DC%2BD2sXhtlGis7nN 10.1056/NEJMoa070594 18032762 (Pubitemid 350146107)
3. DM Weber C Chen R Niesvizky M Wang A Belch EA Stadtmauer, et al. 2007 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2133 2142 1:CAS:528:DC%2BD2sXhtlGis7bM 10.1056/NEJMoa070596 18032763 (Pubitemid 350146108)
4. SV Rajkumar S Jacobus NS Callander R Fonseca DH Vesole ME Williams, et al. 2010 Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 29 37 1:CAS:528:DC%2BC3cXjslKrsg%3D%3D 10.1016/S1470-2045(09)70284-0 19853510
5. S Iida T Chou S Okamoto H Nagai K Hatake H Murakami, et al. 2010 Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma Int J Hematol 92 118 126 1:CAS:528:DC%2BC3cXpsFOktrw%3D 10.1007/s12185-010-0624-7 20559759
6. H Quach D Ritchie AK Stewart P Neeson S Harrison MJ Smyth, et al. 2010 Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Leukemia 24 22 32 1:CAS:528:DC%2BC3cXltlejsg%3D%3D 10.1038/leu.2009.236 19907437
7. A Ferrajoli BN Lee EJ Schlette SM O'Brien H Gao S Wen, et al. 2008 Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia Blood 111 5291 5297 1:CAS:528:DC%2BD1cXntFWnsr4%3D 10.1182/blood-2007-12-130120 18334676
8. G Aue N Njuguna X Tian S Soto T Hughes B Vire, et al. 2009 Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia Haematologica 94 1266 1273 1:CAS:528:DC%2BD1MXhtlanurrN 10.3324/haematol.2009.005835 19734418
9. J Yang M Wezeman X Zhang P Lin M Wang J Qian, et al. 2007 Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis Cancer Cell 12 252 265 10.1016/j.ccr.2007.08.008 17785206 (Pubitemid 47333419)